默克雪兰诺公司(Merck Serono)和纽隆制药公司(Newron Pharmaceuticals)公布了对其合作开发的小分子单胺氧化酶B抑制剂safinamide进行的一项名为Study018的双盲、安慰剂对照的Ⅲ期临床研究结果。该实验为期18个月,尽管未完全达到研究的主要考察指标,但两家公司仍称该药有望成为治疗帕金森病的特效药。此前,两家公司曾报道过一项名为Study016、有669名患者参加、为期6个月的Ⅲ期研究结果。该项研究对在左旋多巴治 Merck Serono and Newron Pharmaceuticals unveiled a double-blind, placebo-controlled phase III study called Study018 for its co-developed small molecule monoamine oxidase B inhibitor safinamide, Clinical research results. The trial, which lasted 18 months, said the two companies are still claiming to be a cure for Parkinson’s disease, although they did not fully meet the main study targets. Previously, the two companies reported a study called Study016, 669 patients participated in a 6-month phase III study. The study on levodopa treatment